PET/MRI Breast Imaging in Assessing Estrogen Receptor Status in Patients with Ductal Breast Carcinoma In Situ

Inclusion Criteria

• Diagnosis of biopsy-proven DCIS without invasion or microinvasion measuring at least 1.0 cm in diameter by any imaging modality
• Undergoing diagnostic breast MRI ordered by the referring clinician for staging and extent of disease

Exclusion Criteria

• Inability or unwillingness to provide informed consent to the study
• Surgery, radiation, neoadjuvant chemo/endocrine therapy for the current malignancy prior to study enrollment
• Patients currently taking or have taken an ER-blocking medication (e.g. tamoxifen, raloxifene) within 6 weeks prior to study enrollment
• Pregnant or lactating women
• Patient with intolerance or contraindications for MRI or gadolinium-based contrast agents
• Patient girth exceeds the bore of the MRI/PET scanner
• Patients requiring conscious sedation for imaging
• Patients with a history of allergic reaction attributable to compounds of similar chemical or biologic composition to FES
• Patients in liver failure as judged by the patient’s physician, due to the hepatobiliary clearance of 18F-FES
• Patients requiring intravenous (IV) conscious sedation for imaging are not eligible; patients requiring mild, oral anxiolytics for the clinical MRI scan will be allowed to participate as long as the following criteria are met: * The patient has their own prescription for the medication * The informed consent process is conducted prior to the self-administration of the medication * The patient comes to the research visit with a driver or an alternative plan for transportation (e.g. Uber, taxi, etc.)